The award is a positive reputational signal but lacks financial or operational catalysts. Monitor for upcoming pipeline data readouts or regulatory milestones that could drive valuation.
Price Chart
Executive Summary
Autolus Therapeutics received the 2026 Prix Galien UK Award for Best Biotechnology Product, a prestigious industry recognition for its T cell therapy innovation. The award is a non-financial validation of the company's scientific platform and commercial-stage status, but does not directly impact revenue, pipeline milestones, or near-term financials.
Key Facts
- Autolus won the 2026 Prix Galien UK Award for Best Biotechnology Product.
- The award is selected by a 12-expert UK Awards Committee.
- Prix Galien is described as the equivalent of the Nobel Prize in biopharmaceutical research.
- Autolus is a commercial-stage biopharmaceutical company with a marketed therapy and pipeline in hematological malignancies, solid tumors, and autoimmune diseases.
Financial Impact
No financial figures disclosed; award provides reputational benefit but no direct revenue or cost impact.
Risk Factors
- Award does not change commercial traction, competitive positioning, or regulatory timelines.
- No financial guidance or pipeline updates provided in the release.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310914 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 12, 2026 20d ago | S-3 | $1.94 $1.94 | · 0.00% | ▼ −0.11% | $1.78 (−8.25%) |
Aug 11, 2026 7w ago | 8-K | $2.33 $2.29 | ▼ −1.72% | ▼ −1.31% | $1.78 (−23.61%) |
Aug 3, 2026 8w ago | 8-K | $1.82 $2.07 | ▲ +13.74% | ▲ +11.71% | $1.78 (−2.20%) |
Aug 3, 2026 8w ago | 8-K | $1.82 $2.07 | ▲ +13.74% | ▲ +11.71% | $1.78 (−2.20%) |
Jun 12, 2026 16w ago | Press Release | $1.56 $1.51 | ▼ −3.21% | ▼ −3.88% | $1.78 (+14.10%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.56 $1.53 | ▲ +1.92% | ▲ +2.36% | $1.78 (−14.10%) |
Jun 9, 2026 16w ago | 8-K | $1.46 $1.50 | ▼ −2.74% | ▼ −0.33% | $1.78 (−21.92%) |
May 21, 2026 19w ago | Press Release | $1.70 $1.84 | ▲ +8.24% | ▲ +6.58% | $1.78 (+4.71%) |
May 14, 2026 20w ago | 8-K | $1.59 $1.65 | ▲ +3.77% | ▲ +4.49% | $1.78 (+11.95%) |
May 14, 2026 20w ago | Press Release | $1.59 $1.65 | ▲ +3.77% | ▲ +4.49% | $1.78 (+11.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access